IMDX
NASDAQ · Biotechnology
Insight Molecular Diagnostic
$3.10
-0.18 (-5.49%)
Open$3.08
Previous Close$3.28
Day High$3.18
Day Low$2.88
52W High$15.94
52W Low$11.01
Volume—
Avg Volume555.2K
Market Cap209.82M
P/E Ratio40.04
EPS$0.37
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+461.6% upside
Current
$3.10
$3.10
Target
$17.41
$17.41
$14.05
$17.41 avg
$26.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.94M | 22.03M | 22.77M |
| Net Income | 4.47M | 4.29M | 5.70M |
| Profit Margin | 20.4% | 19.5% | 25.1% |
| EBITDA | 9.15M | 9.08M | 9.52M |
| Free Cash Flow | 3.10M | 3.08M | 2.32M |
| Rev Growth | -4.7% | +9.7% | +22.0% |
| Debt/Equity | 1.02 | 1.02 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |